Abubakar Sadiq Yakubu

Mr. Abubakar Sadiq Yakubu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2026 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
FAFatima Fatima Abdurrazaq
Fatima Fatima Abdurrazaq
EOEnayi Onaji
Enayi Onaji
AYAbubakar Sadiq Yakubu
Abubakar Sadiq Yakubu
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
Diabetes mellitus is a major global public health challenge associated with significant morbidity and mortality. Although α-glucosidase inhibitors are widely used in the management of postprandial hyperglycemia, currently available drugs are often associated with undesirable side effects, reduced patient compliance, and limited therapeutic effectiveness. Consequently, there is a growing need to identify novel inhibitors with improved efficacy and safety profiles. This study aimed to investigate the potential of 14 chalcone and 4 pyrazoline compounds (18 compounds in total) as potential α-glucosidase inhibitors using computational approaches. A library of compounds was designed using ChemDraw and subjected to geometry optimization with Spartan14 software. Drug-likeness, pharmacokinetic, and toxicity properties were assessed using SwissADME and ProTox-II servers. Molecular docking studies were performed against the α-glucosidase enzyme (PDB ID: 8YIE) using AutoDock Vina to determine binding affinities and interactions within the enzyme’s active site. ADMET analysis revealed that the majority of the compounds exhibited favorable pharmacokinetic characteristics and acceptable safety profiles. Among the screened compounds, compounds PC1 and PHPY exhibited the most favorable docking scores at −9.8 kcal/mol and −9.3 kcal/mol, respectively, surpassing the reference ligand acabose (AC1) (−8.8 kcal/mol). Detailed interaction analysis revealed the formation of key hydrogen bonds, π–π stacking, and π–alkyl interactions with critical active-site residues. These findings suggest that the investigated chalcone and pyrazoline compounds may be promising candidates for further investigation as potential α-glucosidase inhibitors. However experimental enzyme inhibition assays and appropriate safety studies are necessary to validate their predicted biological activity and establish their safety profiles.

20 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
AYAbubakar Sadiq Yakubu
Abubakar Sadiq Yakubu
AHAsmau Nasiru Hamza
Asmau Nasiru Hamza
IAIdris Yunusa Abdullahi
Idris Yunusa Abdullahi
MAmaryam abdullahi
maryam abdullahi
Idris AbdullahiIdris Abdullahi
Idris Abdullahi
IAIDRIS UMAR ALFULANII
IDRIS UMAR ALFULANII
Depression is a debilitating neuropsychiatric disorder and a leading cause of disability worldwide, with current therapeutic options often limited by delayed onset of action, inadequate efficacy, and undesirable side effects. The quinoline scaffold, a privileged structure in medicinal chemistry, has been reported to possess a wide spectrum of pharmacological properties, including central nervous system (CNS) modulation. In this study, two novel 2,4-diphenylquinoline derivatives—CMPD1 [2-(4-methoxyphenyl)-4-phenylquinoline] and CMPD2 [2-(2,4-dichlorophenyl)-4-phenylquinoline]—were rationally designed based on structure–activity relationship (SAR) insights and synthesized via the Friedländer condensation of appropriately substituted anilines with carbonyl precursors. Purification was achieved through recrystallization, and structural confirmation was performed using Fourier-transform infrared (FT-IR) spectroscopy, proton nuclear magnetic resonance (NMR), and carbon-13 NMR spectroscopy, confirming the expected chemical shifts and diagnostic signals for quinoline derivatives. The pharmacological activity was evaluated using murine models for antidepressant screening: the Forced Swim Test (FST) and Tail Suspension Test (TST). Both compounds produced statistically significant reductions in immobility time compared to the control group (p < 0.05), with CMPD2 showing slightly enhanced activity. The results suggest that electron-donating and electron-withdrawing substituents influence antidepressant potency, potentially through modulation of CNS receptor binding. These findings validate 2,4-diphenylquinoline derivatives as promising antidepressant leads, meriting further optimization, in vivo pharmacokinetic studies, and mechanistic investigations to establish their clinical translation potential.